Today, Supernus Pharmaceuticals Inc. (SUPN) Stock Rating Upgrade by The Zacks Investment Research

Today, Supernus Pharmaceuticals Inc. (SUPN) Stock Rating Upgrade by The Zacks Investment Research

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The firm currently has a $24.00 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research’s price target points to a potential upside of 5.73% from the company’s previous close.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Separately, Jefferies Group reissued a “buy” rating and issued a $28.00 target price (up from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $24.75.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 21.65 on Tuesday. The company has a 50-day moving average price of $21.24 and a 200 day moving average price of $21.37. Supernus Pharmaceuticals has a one year low of $9.51 and a one year high of $26.84. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of 44.18 and a beta of 1.86.

In other news, CFO Gregory S. Patrick sold 2,000 shares of the company’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $25.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now directly owns 3,616 shares of the company’s stock, valued at $90,400. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 6.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Fund Advisors increased its position in shares of Supernus Pharmaceuticals by 27.5% in the third quarter. BlackRock Fund Advisors now owns 3,952,348 shares of the specialty pharmaceutical company’s stock worth $97,742,000 after buying an additional 853,080 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals by 10.0% in the second quarter. Vanguard Group Inc. now owns 1,956,476 shares of the specialty pharmaceutical company’s stock worth $39,854,000 after buying an additional 177,648 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Supernus Pharmaceuticals by 13.8% in the third quarter. Acadian Asset Management LLC now owns 1,737,526 shares of the specialty pharmaceutical company’s stock worth $42,967,000 after buying an additional 210,249 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Supernus Pharmaceuticals by 2.1% in the third quarter. Bank of New York Mellon Corp now owns 1,694,026 shares of the specialty pharmaceutical company’s stock worth $41,892,000 after buying an additional 34,422 shares during the last quarter. Finally, Fiera Capital Corp acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth about $27,544,000. 93.47% of the stock is currently owned by hedge funds and other institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Related posts

Leave a Comment